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Background:  Kidney function is critical in homocysteine clearance, and plasma homocysteine level is frequently increased in 
patients with renal failure. On the other hand, recent studies in animals have shown that hyperhomocysteinemia induces renal 
injury. In this study, we determined whether hyperhomocysteinemia can be a risk factor for the development of microalbuminu-
ria in patients with type 2 diabetes. 
Methods:  A nested case-control study. Of 887 patients with type 2 diabetes who did not have microalbuminuria at baseline, 76 
developed microalbuminuria during follow-up (mean, 36.0 ± 11.7 months; range, 18 to 76 months). The control group consisted 
of 152 age- and sex-matched subjects who did not develop microalbuminuria. Baseline plasma homocysteine concentrations were 
measured in stored samples. 
Results:  Baseline plasma homocysteine concentrations and mean HbA1C levels during follow-up were significantly higher in 
patients who developed microalbuminuria than in those who remained normoalbuminuric. Multivariate logistic regression analy-
sis showed that baseline plasma homocysteine level and mean HbA1C were independent predictors of microalbuminuria in type 
2 diabetes. 
Conclusion:  Hyperhomocysteinemia was associated with increased risk of microalbuminuria in patients with type 2 diabetes 
supporting the concept that hyperhomocysteinemia has an etiologic role in the pathogenesis of diabetic nephropathy.
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INTRODUCTION
The public health burden of diabetic nephropathy has increased 
rapidly along with the world-wide increase in the prevalence of 
type 2 diabetes. Diabetic nephropathy deteroriates quality of life 
and also decreases life expectancy. Microalbuminuria is a pre-
dictor of overt proteinuria in patients with diabetes [1], as well 
as being a risk factor for cardiovascular disease in patients with 
type 2 diabetes and in normal subjects [2]. Although poor gly-
cemic control and high blood pressure are known to increase 
the risk of microalbuminuria in patients with type 2 diabetes 
[3-5], little is known regarding other factors that predispose 
these individuals to the development of microalbuminuria. 
  Hyperhomocysteinemia occurs frequently in patients with 
renal failure [6]. As proper renal function is crucial to homo-
cysteine metabolism [7], it is generally believed that hyperho-
mocysteinemia in renal failure is secondary to decreased renal 
function. On the other hand, recent studies in animals showed 
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that hyperhomocysteinemia induces glumerulosclerosis and 
podocyte injury [8-12]. It has also been reported that hyper-
homocysteinemia precedes the development of overt protei-
nuria in patients with type 2 diabetes [13]. These findings sug-
gest that hyperhomocysteinemia may play a pathogenic role in 
the genesis of diabetic nephropathy. However, it is not yet clear 
whether hyperhomocysteinemia can be a risk factor for early 
diabetic nephropathy. We therefore assessed whether hyper-
homocysteinemia is an independent risk factor for the devel-
opment of microalbuminuria in patients with type 2 diabetes.
METHODS
Study protocol 
This study was performed in patients with type 2 diabetes at-
tending a diabetes clinic of a university hospital (the Asan Med-
ical Center) in Seoul, South Korea. From January 2002 to De-
cember 2004, we recruited 1,226 patients with type 2 diabetes 
and normoalbuminuria at the time of registry and with urine 
collection. Patients were excluded if any one of the following 
conditions was present: plasma creatinine > 1.2 mg/dL, con-
gestive heart failure, or a major concurrent illness such as can-
cer or end-stage pulmonary or liver disease. After obtaining 
written informed consent from each individual and the ap-
proval of our institutional review committee, we obtained 
baseline blood samples from each patient, as well as recording 
patients age, sex, blood pressure, duration of diabetes and other 
clinical information. Blood samples were centrifuged and 
stored at -70°C. 
  At baseline, patients collected timed overnight urine sam-
ples 2 or 3 times [5], and their baseline albumin excretion rate 
was determined by radioimmunoassay (Beckman Coulter, 
Galway, Ireland). Individuals were considered normoalbumin-
uric if urinary albumin excretion (UAE) was consistently un-
der 20 mg/min. Patients were followed every 3 months. At each 
visit, blood pressure, plasma glucose, lipid profiles, and HbA1C 
were measured. UAE was measured twice yearly from timed 
overnight urine collections. If the UAE value exceeded 20 mg/
min, it was measured twice more at 3-month intervals. Persis-
tent microalbuminuria was defined as UAE > 20 mg/min on at 
least two of the three measurements.
  By June 2007, we collected data on 887 patients who had 
been followed for more than 18 months (mean follow up, 36.0 
± 11.7 months; range, 18 to 76 months). Among these, 76 sub-
jects developed microalbuminuria during the follow-up peri-
od, and we defined them as cases. For each case, we randomly 
and individually selected two controls who were matched on 
age and sex. 
Laboratory analyses 
Fasting plasma glucose, HbA1C, C-peptide, creatinine, high 
sensitivity C-reactive protein (hsCRP), total cholesterol, trig-
lycerides, high density lipoptoein cholesterol (HDL-C), low 
density lipoptoein cholesterol (LDL-C) and free fatty acid con-
centrations were measured by standard procedures. Homo-
cysteine concentrations in the stored plasma samples were 
measured by competitive immunoassay analyzed on the AD-
VIA Centaur (Bayer Diagnostics, Tarrytown, NY, USA). Esti-
mated glomerular filtration rate (GFR) was calculated using 
Cockroft & Gault equation. Matched case-control pairs were 
handled identically and assayed in random order in the same 
analytical run. 
Statistical analyses 
Results are reported as mean ± standard deviation or median 
with interquartile range. Statistical analysis was performed us-
ing SPSS software (version 12.0; SPSS Inc., Chicago, IL, USA). 
Student’s t-test or Mann Whitney U test was used for continu-
ous variables, and the χ
2 test for analysis of discrete variables, 
with all P values reported for two-sided tests. Values of P < 0.05 
were considered significant. 
  To determine the associations of potential determinants 
with the development of microalbuminuria, we performed 
multiple logistic regression analysis with backward elimina-
tion of variables, using seven variables that may be of biologi-
cal significance (i.e., baseline homocysteine and estimated 
GFR levels, baseline UAE, follow-up duration, mean systolic 
blood pressure and HbA1C levels during follow-up, past and 
present cardiovascular disease). The presence of microalbu-
minuria at follow-up was the dependent variable and potential 
determinants for development of microalbuminuria were in-
dependent variables. Variables having skewed distribution such 
as baseline plasma homocysteine concentrations, and follow-
up duration were natural log (Ln)-transformed before analysis. 
Values of P < 0.05 were considered significant. The dose-re-
sponse relationship for homocysteine was determined by cal-
culating odds ratios for developing microalbuminuria for sev-
eral total homocysteine concentration ranges (9.1 to 14.0, 14.1 
to 19.0, and > 19.0 mmol/L) with total homocysteine concen-
trations < 9.1 mmol/L as reference [14]. 202
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RESULTS
Table 1 shows the baseline clinical characteristics of patients 
who did and did not develop microalbuminuria. We observed 
no significant between-group differences in baseline age, sex, 
body mass index (BMI), duration of diabetes, fasting plasma 
glucose, systolic and diastolic blood pressure, UAE, and HbA1C, 
total cholesterol, C-peptide, creatinine, estimated GFR, hsCRP, 
free fatty acid concentrations, prevalence of hypertension, the 
use of antihypertensive or anti-diabetic medications and past 
and present cardiovascular disease history. There was no sta-
tistically significant correlation between Ln plasma homo-
cysteine level and baseline creatinine levels or UAE (Fig. 1A 
and B).
  Baseline concentrations of plasma homocysteine, however, 
were significantly higher among patients who developed mi-
croalbuminuria than among patients who were normoalbu-
minuric during the follow-up period (11.8 ± 3.7 mmol/L vs. 
10.3 ± 3.1 mmol/L, P = 0.003). There was a significant positive 
correlation between baseline Ln plasma homocysteine levels 
Table 1.  Clinical characteristics at baseline relative to albuminuria status at follow-up
Patients who did not develop 
microalbuminuria
Patients who developed  
microalbuminuria
P value
a
n (M/F) 152 (106/46) 76 (53/23) 0.762
Age, yr 57 (48 to 65) 57 (48 to 65) 0.821
BMI, kg/m
2 25.2 ± 3.2 25.4 ± 2.8 0.722
Duration of diabetes, yr 5 (3 to 10) 6 (4 to 10) 0.804
Fasting plasma glucose, mg/dL 153.0 ± 44.9 146.6 ± 41.5 0.295
HA1C, % 8.1 ± 1.7 8.3 ± 1.9 0.274
Systolic blood pressure, mm Hg 134.4 ± 16.6 135.0 ± 14.7 0.801
Diastolic blood pressure, mm Hg 79.4 ± 10.7 78.6 ± 9.3 0.588
Total cholesterol, mg/dL 189.4 ± 36.8 189.8 ± 41.3 0.939
C-peptide, nmol/L 1.8 (1.3 to 2.2) 1.8 (1.3 to 2.4) 0.999
Creatinine, mg/dL 0.88 ± 0.17 0.92 ± 0.21 0.489
eGFR, mL/min/1.73m
2 92.6 ± 23.6 94.1 ± 30.9 0.739
hsCRP, mg/dL 0.13 (0.08 to 0.25) 0.12 (0.08 to 0.2) 0.568
Free fatty acid, mEq/L 680 (516 to 954) 746 (530 to 977) 0.290
Homocysteine, mmol/L 10.3 ± 3.1 11.8 ± 3.7 0.003
Baseline urinary albumin excretion, mg/min 10.6 (7.9 to 14.2) 11.4 (8.0 to 16.1) 0.369
Baseline hypertension prevalence 59 (38.8) 33 (43.4) 0.567
Baseline ARB or ACEi medication 36 (23.7) 27 (35.5) 0.083
Baseline statin medication 47 (30.9) 25 (32.9) 0.765
Baseline anti-diabetic therapy
   Sulfonylurea 124 (81.6) 61 (80.3) 0.624
   Metformin 93 (61.2) 45 (59.2) 0.235
   Other hypoglycemic agents 61 (40.1) 32 (47.8) 0.542
   Insulin alone 12 (7.9) 9 (11.8) 0.375
   Insulin + oral agents  25 (16.4) 10 (13.2) 0.440
Past and present CVD history 22 (14.5) 14 (18.4) 0.443
Data are means ± standard deviation or median (interquartile range), n (%). 
BMI, body mass index; ARB, angiotensin receptor blockers; ACEi, angiotensin converting enzyme inhibitors; eGFR, estimated glomerular fil-
tration rate; CVD, cardiovascular disease. 
aAppropriate bivariate statistic. 203
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and follow-up UAE (Fig. 1C). 
  There were no significant between group differences in du-
ration of follow up, mean systolic blood pressure, mean diastol-
ic blood pressure, and mean total cholesterol (Table 2). Howev-
er, mean HbA1C during follow-up were significantly higher 
among patients who developed microalbuminuria than among 
patients who remained normoalbuminuric (7.5 ± 0.9% vs. 8.0 
± 1.2%, P = 0.001). 
  Multivariate binary logistic regression analysis with back-
ward elimination of variables was performed using baseline 
Ln plasma homocysteine and estimated GFR levels, baseline 
UAE, Ln follow-up duration, mean systolic blood pressure and 
Table 2.  Clinical characteristics during follow-up period relative to albuminuria status at follow-up
Patients who did not develop  
microalbuminuria
Patients who developed  
microalbuminuria
P value
a
n (M/F) 152 (106/46) 76 (53/23) 0.762
Mean Fasting plasma glucose, mg/dL 141.0 ± 29.8 149.1 ± 34.7 0.071
Mean HbA1C, % 7.5 ± 0.9 8.0 ± 1.2 0.001
Mean systolic blood pressure, mm Hg 134.2 ± 16.2 135.6 ± 15.6 0.651
Mean diastolic blood pressure, mm Hg 76.2 ± 8.4 76.2 ± 7.2 0.955
Mean total cholesterol, mg/dL 179.2 ± 26.0 183.4 ± 26.0 0.249
Follow up duration, mon 31.5 (29 to 40) 30.5 (27 to 39) 0.192
aAppropriate bivariate statistic. 
Table 3.  Multiple logistic regression analysis with the background elimination method using 6 biologically important variables 
as independent variables, and the development of microalbuminuria as the dependent variable
Independent variables
Partial regression
coefficient
Standard
error
Odds ratio
(β)
95 % CI P value
Ln homocysteine 1.642 0.511 5.167 1.898 to 14.067 0.001
Mean HbA1C 0.560 0.153 1.750 1.297 to 2.362 <0.001
The multivariate model was adjusted for baseline estimated glomerular filtration rate, baseline urinary albumin excretion, mean systolic blood 
pressure, and follow-up duration and past and previous cardiovascular disease history. Natural log transformed (Ln) data were modeled for 
creatinine, homocysteine and follow-up duration. CI, confidence interval.
C
r
e
a
t
i
n
i
n
e
,
 
m
g
/
d
L
Ln homocysteine, mmol/L
NS 1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.5  1.0  1.5  2.0  2.5  3.0  3.5
B
a
s
e
l
i
n
e
 
U
A
E
,
 
m
g
/
m
i
n
Ln homocysteine, mmol/L
NS 200
150
100
50
0
0.5  1.0  1.5  2.0  2.5  3.0  3.5
F
o
l
l
o
w
-
u
p
 
U
A
E
,
 
m
g
/
m
i
n
Ln homocysteine, mmol/L
r = 0.259, P < 0.001 200
150
100
50
0
0.5  1.0  1.5  2.0  2.5  3.0  3.5
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mean HbA1C levels during follow-up, and past and present 
cardiovascular disease history as independent variables, and 
microalbuminuria development as the dependent variable. Mean 
HbA1C (odds ratio [OR], 1.750; range, 1.297 to 2.362; P < 0.001) 
and Ln homocysteine levels (OR, 5.167; range, 1.898 to 14.067; 
P = 0.001) were independent predictors of microalbuminuria 
development (Table 3). 
  We divided the total subjects in whom baseline total homo-
cysteine concentrations were measured (n = 887) into those 
with baseline homocysteine concentrations of < 9.1, 9.1 to 14.0, 
14.1 to 19.0, and > 19.0 mmol/L. The cumulative incidence of 
microalbuminuria in these 4 groups of patients was 6.4% 
(21/326), 7.6% (33/436), 17.1% (18/105), and 20.0% (4/20), re-
spectively (P value for trend = 0.001, Fig. 2). After adjustment 
for age, sex, baseline HbA1C and plasma creatinine concen-
trations, the odds ratios for microalbuminuria, relative to base-
line homocysteine concentrations of < 9.1 mmol/L, were 1.3 (95% 
confidence interval [CI], 0.7 to 2.4), 3.6 (95% CI, 1.8 to 7.3), and 
4.6 (95% CI, 1.4 to 15.4) for baseline homocysteine concentra-
tions of 9.1 to 14.0, 14.1 to 19.0, and > 19.0 mmol/L, respec-
tively. When homocysteine level categories were replaced by 
homocysteine concentration as a continuous variable, a 5 
mmol/L increase in homocysteine concentration was associat-
ed with a 1.8-fold (95% CI, 1.3 to 2.5; P < 0.001) increase in the 
risk of developing microalbuminuria, after adjustment for age, 
sex, baseline HbA1c and creatinine levels.
DISCUSSION
In this study, we show that hyperhomocysteinemia is an inde-
pendent risk factor for the development of microalbuminuria 
in patients with type 2 diabetes. Baseline plasma homocysteine 
concentrations were significantly higher in normoalbuminuric 
patients who developed microalbuminuria during follow-up 
than in normoalbuminuric patients who did not develop mi-
croalbuminuria. These findings are in agreement with previ-
ous cross-sectional and longitudinal studies [13,15], which 
showed associations between plasma homocysteine levels and 
overt proteinuria in diabetic patients. Although homocysteine 
concentrations have been found to be associated with microal-
buminuria development in non-diabetic subjects [14], to our 
knowledge, the present study is the first to show an association 
between plasma homocysteine concentration and develop-
ment of microalbuminuria in diabetic individuals. Although 
the previous study by Jager et al. was unable to find a relation-
ship between hyperhomocysteinemia and microalbuminuria 
developement in diabetic patients [14], our results showed the 
significant relationship in patients with type 2 diabetes be-
cause of a larger sample size. 
  Kidney function is critical for homocysteine clearance [7], 
and hyperhomocysteinemia occurs frequently in patients with 
renal failure [6,16]. Thus it can be asked whether the associa-
tion between plasma homocysteine levels and urinary albumin 
excretion is attributed to associated changes in renal function 
[16,17]. In our study, however, only patients who were normoal-
buminuric at baseline were included. Although we did not mea-
sure glomerular filtration rate in all of these patients, renal 
function is known to deteriorate following (micro)albuminu-
ria [18,19]. All of our subjects had normal plasma creatinine 
levels (below 1.2 mg/dL), and there was no significant correla-
tion between baseline Ln plasma homocysteine level and base-
line UAE or baseline plasma creatinine concentration. On the 
other hand, follow-up UAE level was significantly correlated 
with baseline Ln plasma homocysteine concentration. 
  Homocysteine has been shown to cause vascular disease 
and endothelial damage [20-22]. In addition, recent studies 
suggested that homocysteine is toxic to kidney tissues. Diet-
induced chronic hyperhomocysteinemia could induce arterial 
and arteriolar thickening, and tubulointerstitial and podocyte 
injury in the kidney [8,9]. Regarding the mechanism of homo-
cysteine-induced glomerular injury, homocysteine was shown 
to activate MAP kinases and to induce endoplasmic reticulum 
stress in cultured mesangial cells [10]. It was also shown that 
homocysteine stimulates ceramide-mediated redox signaling 
[11], and increases monocyte chemoattractant protein-1 ex-
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pression in the kidney via nuclear factor-kappaB activation 
[12]. These studies suggest that hyperhomocysteinemia may 
play a causative role in early renal injury, in addition to being a 
marker of impaired renal function [16,17].
  Poor glycemic control and high blood pressure are known 
to increase the risk of microalbuminuria in patients with type 
2 diabetes [3-5]. As expected, we found significant differences 
between cases and controls in mean HbA1C levels during fol-
low-up. In addition, multivariate logistic regression analyses 
showed that basal Ln plasma homocysteine levels remained a 
significant independent variable, even after correcting for 
mean HbA1C levels and other important variables. We also 
found that plasma homocysteine concentration > 14.0 mmol/L 
was associated with a marked increase in the risk of microal-
buminuria. For each 5 mmol/L increase in homocysteine con-
centration, the risk of developing microalbuminuria increased 
by about 80%. This is in line with previous studies showing 1.3 
to 1.6 fold increase per 5 mmol/L increase in homocysteine 
concentration in the risk for microalbuminuria in non-diabet-
ic subjects [23] and of overt proteinuria in diabetic subjects 
[13]. 
  Although microalbuminuria in type 1 diabetes is regarded 
as an early manifestation of diabetic nephropathy, the mean-
ing of microalbuminuria in type 2 diabetes is more complex. 
The metabolic syndrome and obesity, which frequently accom-
pany type 2 diabetes, predispose these individuals to microalbu-
minuria [24], and plasma homocysteine level is frequently in-
creased in patients with metabolic syndrome [25,26]. 
  In the present study, 125 among 887 patients had marked 
hyperhomocysteinemia (> 14 mmol/L) and increased risk for 
developing microalbuminuria. Since homocysteine has been 
shown to cause cardiovascular disease and endothelial damage 
[20-22], hyperhomocysteinemia in diabetic patients may lead 
to endothelial dysfunction in systemic and renal blood vessels, 
and predispose these patients to increased risks of both car-
diovascular disease and microalbuminuria. 
  In our study, we used nested cohort design with a relatively 
small number of patients attending a single center. For many 
research questions, the nested case-control design potentially 
gives significant reductions in time, cost, and effort of data col-
lection and analysis, compared with the full cohort approach, 
with a relatively minor loss in statistical efficiency [27,28]. How-
ever, future studies with a larger population and longer dura-
tion of follow-up are needed to provide more definitive con-
clusion.
  In summary, we have shown that hyperhomocysteinemia is 
associated with a higher incidence of microalbuminuria in pa-
tients with type 2 diabetes mellitus. Further studies in larger 
populations are needed to confirm these findings, and to test 
whether lowering of plasma homocysteine by dietary manipu-
lation [29] is helpful for patients at risk for diabetic nephropa-
thy. 
ACKNOWLEDGEMENT
Support: This work was supported by the Korea Science and 
Engineering Foundation (KOSEF) grants funded by the Min-
istry of Science and Technology (M10642140004-06N4214- 
00410: K.U.L. and M10753020003-08N5302-00310: J.Y.P. and 
NRL M1040000000804J000000810: J.Y.P.) and a grant (2008-
122) from Asan Institute for Life Sciences, Seoul, Korea. 
Conflict of interest: None.
REFERENCES 
1. Mogensen CE. Microalbuminuria predicts clinical proteinuria 
and early mortality in maturity-onset diabetes. N Engl J Med 
1984;310:356-60.
2. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogw-
erf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. 
Albuminuria and risk of cardiovascular events, death, and 
heart failure in diabetic and nondiabetic individuals. JAMA 
2001;286:421-6.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, 
Cull CA, Hadden D, Turner RC, Holman RR. Association of 
glycaemia with macrovascular and microvascular complica-
tions of type 2 diabetes (UKPDS 35): prospective observation-
al study. BMJ 2000;321:405-12.
4. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk 
factors for development of incipient and overt diabetic neph-
ropathy in patients with non-insulin dependent diabetes mel-
litus: prospective, observational study. BMJ 1997;314:783-8.
5. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU. Inci-
dence and determinants of microalbuminuria in Koreans with 
type 2 diabetes. Diabetes Care 1998;21:530-4.
6. Hoffer LJ. Testing the homocysteine hypothesis in end-stage 
renal disease: problems and a possible solution. Kidney Int 
2006;69:1507-10.
7. Ruan L, Chen W, Srinivasan SR, Xu J, Toprak A, Berenson GS. 
Plasma homocysteine is adversely associated with glomerular 206
Cho E-H, et al.
Korean Diabetes J 2010;34:200-206 www.e-kdj.org
filtration rate in asymptomatic black and white young adults: 
the Bogalusa heart study. Eur J Epidemiol 2009;24:315-9.
8. Kumagai H, Katoh S, Hirosawa K, Kimura M, Hishida A, 
Ikegaya N. Renal tubulointerstitial injury in weanling rats with 
hyperhomocysteinemia. Kidney Int 2002;62:1219-28.
9. Yi F, dos Santos EA, Xia M, Chen QZ, Li PL, Li N. Podocyte 
injury and glomerulosclerosis in hyperhomocysteinemic rats. 
Am J Nephrol 2007;27:262-8.
10. Ingram AJ, Krepinsky JC, James L, Austin RC, Tang D, Salap-
atek AM, Thai K, Scholey JW. Activation of mesangial cell 
mapk in response to homocysteine. Kidney Int 2004;66:733-45.
11. Yi F, Zhang AY, Li N, Muh RW, Fillet M, Renert AF, Li PL. In-
hibition of ceramide-redox signaling pathway blocks glomeru-
lar injury in hyperhomocysteinemic rats. Kidney Int 2006;70: 
88-96.
12. Hwang SY, Woo CW, Au-Yeung KK, Siow YL, Zhu TY, O K. 
Homocysteine stimulates monocyte chemoattractant protein-1 
expression in the kidney via nuclear factor-kappaB activation. 
Am J Physiol Renal Physiol 2008;294:F236-44.
13. Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, 
Narayan KM, Knowler WC, Hanson RL. Homocysteine as a 
risk factor for nephropathy and retinopathy in type 2 diabetes. 
Diabetologia 2003;46:766-72.
14. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter 
LM, Donker AJ, Stehouwer CD. Serum homocysteine levels are 
associated with the development of (micro)albuminuria: The 
Hoorn Study. Arterioscler Thromb Vasc Biol 2001;21:74-81.
15. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva 
A, Gonzalez-Sastre F, Blanco-Vaca F. Plasma homocysteine is 
related to albumin excretion rate in patients with diabetes mel-
litus: a new link between diabetic nephropathy and cardiovas-
cular disease? Diabetologia 1998;41:684-93.
16. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, 
Berne C. Plasma total homocysteine and cysteine in relation to 
glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 
55:1028-35.
17. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh 
P, Fulcher GR. The relationship among homocysteine, creati-
nine clearance, and albuminuria in patients with type 2 diabe-
tes. Diabetes Care 2001;24:1805-9.
18. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg 
J, Warram JH, Krolewski AS. Microalbuminuria and the risk 
for early progressive renal function decline in type 1 diabetes. J 
Am Soc Nephrol 2007;18:1353-61.
19. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman 
RR. Development and progression of nephropathy in type 2 
diabetes: the United Kingdom Prospective Diabetes Study 
(UKPDS 64). Kidney Int 2003;63:225-32.
20. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-
catalyzed hydrogen peroxide generation from homocysteine. J 
Clin Invest 1986;77:1370-6.
21. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, 
Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)
inemia is a risk factor for arterial endothelial dysfunction in 
humans. Circulation 1997;96:2542-4.
22. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. 
Homocysteine metabolism, hyperhomocysteinaemia and vas-
cular disease: an overview. J Inherit Metab Dis 2006;29:3-20.
23. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, 
Bouter LM, Donker AJ, Stehouwer CD. Serum homocysteine 
level and protein intake are related to risk of microalbuminu-
ria: the Hoorn Study. Kidney Int 1998;54:203-9.
24. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in 
the metabolic syndrome. J Am Soc Nephrol 2006;17:S81-5.
25. Lee KU. Oxidative stress markers in Korean subjects with in-
sulin resistance syndrome. Diabetes Res Clin Pract 2001;54 
Suppl 2:S29-33.
26. Bjorck J, Hellgren M, Rastam L, Lindblad U. Associations be-
tween serum insulin and homocysteine in a Swedish popula-
tion-a potential link between the metabolic syndrome and hy-
perhomocysteinemia: the Skaraborg project. Metabolism 2006; 
55:1007-13.
27. Ernster VL. Nested case-control studies. Prev Med 1994;23: 
587-90.
28. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura 
K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm 
EB. Inflammatory markers and the risk of coronary heart dis-
ease in men and women. N Engl J Med 2004;351:2599-610.
29. Clarke R, Refsum H, Birks J, Evans JG, Johnston C, Sherliker P, 
Ueland PM, Schneede J, McPartlin J, Nexo E, Scott JM. Screen-
ing for vitamin B-12 and folate deficiency in older persons. Am 
J Clin Nutr 2003;77:1241-7.